The short comparison
Retatrutide and Zepbound are both from Eli Lilly, but they are not at the same stage. Zepbound, also called tirzepatide, is approved for obesity. Retatrutide is investigational and is not FDA approved.
Retatrutide is a triple agonist that acts through GIP, GLP-1, and glucagon receptors. Its trial results are one reason researchers and readers are watching it, but those results do not by themselves prove that one medicine is better for a particular person.
What the main trials reported
In SURMOUNT-1, the top dose of tirzepatide produced 20.9% average weight loss at 72 weeks (source: NEJM SURMOUNT-1, 2022). That result helped set the standard against which retatrutide is often discussed.
In TRIUMPH-1, retatrutide produced 28.3% average weight loss at 80 weeks and 30.3% at 104 weeks. Among top dose participants, 45.3% lost at least 30% of their body weight. The study included 2,339 people (source: Lilly trial readout, 2026).
Those numbers make retatrutide look stronger in informal comparisons. They do not prove that retatrutide beats Zepbound.
No direct trial comparing retatrutide with Zepbound has been completed.
Why separate trials are hard to compare
A head to head study places treatments in the same trial under the same protocol. TRIUMPH-1 and SURMOUNT-1 were separate studies. They ran for different lengths of time, used their own study plans, and enrolled their own participant groups.
Retatrutide's 28.3% average at 80 weeks is higher than the 20.9% average reported for top dose tirzepatide at 72 weeks. It is fair to say that this difference has created head to head buzz. It is not fair to say a direct trial has proven superiority, because no such trial exists.
Time also matters. The 30.3% retatrutide figure came at 104 weeks, while the Zepbound comparison figure came at 72 weeks. Placing those percentages side by side without the study lengths can mislead a reader.
Approval and access are very different
Zepbound is an approved obesity medicine. Retatrutide cannot legally be sold as an approved prescription treatment. Lilly announced that it plans to file a Biologics License Application for retatrutide in the first quarter of 2027. Standard review math points roughly to January through March 2028, while priority review could bring a decision in late 2027.
The realistic retatrutide approval range is late 2027 to the middle of 2028. That estimate is not a promised date. The FDA must review the application and decide whether the evidence supports approval.
There is also no legal compounded retatrutide. The FDA stated on October 1, 2026 that retatrutide cannot be used in compounding under federal law. Online sellers that use the word “research” are not legal substitutes for an approved product.
What we still do not know
Retatrutide has no announced brand name or price. “Bemlayo” is unconfirmed trademark speculation, not a confirmed product name. A future label, if the medicine is approved, would define its approved use and other prescribing information.
We also do not know how a direct retatrutide and Zepbound trial would turn out. Separate trial averages can help explain why researchers are interested, but they cannot answer every clinical question.
How to discuss the choice with a doctor
Today, the choice is not between two approved medicines. Zepbound is approved and retatrutide is still in development. A useful conversation with a qualified health care professional can focus on your health history, goals, risks, insurance, and the approved options available now.
Be cautious if a seller claims to offer retatrutide before approval. Do not assume a compounded or research product is a generic version of a brand drug. No approved retatrutide product currently exists.
The bottom line
TRIUMPH-1 reported higher average weight loss figures for retatrutide than SURMOUNT-1 reported for top dose tirzepatide, but the trials were separate and ran for different lengths of time. Retatrutide remains investigational. Zepbound is approved. Until a direct trial exists, the accurate conclusion is that retatrutide produced striking results and strong comparison buzz, not that it has proven itself better than Zepbound.